Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SZ1003 in advanced hepatocellular carcinoma
NCT07201064Phase 1Not yet recruiting
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of SZ1003 in hepatocellular carcinoma (HCC), sponsored by Guangdong ProCapZoom Biosciences Co., Ltd. Primary endpoints: Adverse events at Week 24 and Serious adverse events at Week 24. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
SZ1003
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07201064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07201064.